Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands. 2021

Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Radiochemistry and Experimental Molecular Imaging, Kerpener Straße 62, 50937, Köln, Germany; Forschungszentrum Jülich GmbH, Germany.

With the aim to obtain potent adenosine A2A receptor (A2AR) ligands, a series of eighteen derivatives of 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide (SYN-115, Tozadenant) were designed and synthesized. The target compounds were obtained by a chemical building block principle that involved reaction of the appropriate aminobenzothiazole phenyl carbamates with either commercially available or readily synthesized functionalized piperidines. Their affinity and subtype selectivity with regard to human adenosine A1-and A2A receptors were determined using radioligand binding assays. Ki values for human A2AR ranged from 2.4 to 38 nM, with more than 120-fold selectivity over A1 receptors for all evaluated compounds except 13k which had a Ki of 361 nM and 18-fold selectivity. The most potent fluorine-containing derivatives 13e, 13g and 13l exhibited Ki values of 4.9 nM, 3.6 nM and 2.8 nM for the human A2AR. Interestingly, the corresponding values for rat A2AR were found to be four to five times higher. Their binding to A2AR was further confirmed by radiolabeling with 18F and in vitro autoradiography in rat brain slices, which showed almost exclusive striatal binding and complete displacement by the A2AR antagonist ZM 241385. We conclude that these compounds represent potential candidates for the visualization of the A2A receptor and open pathways to novel therapeutic treatments of neurodegenerative disorders or cancer.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D016466 CHO Cells CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. CHO Cell,Cell, CHO,Cells, CHO

Related Publications

Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
October 2019, European journal of medicinal chemistry,
Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
February 2024, Molecules (Basel, Switzerland),
Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
April 2008, Bioorganic & medicinal chemistry,
Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
August 2007, Bioorganic & medicinal chemistry,
Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
February 2001, Journal of medicinal chemistry,
Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
March 2024, ACS chemical neuroscience,
Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
June 2013, Yao xue xue bao = Acta pharmaceutica Sinica,
Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
August 2020, Bioorganic chemistry,
Dana R Renk, and Marcel Skraban, and Dirk Bier, and Annette Schulze, and Erika Wabbals, and Franziska Wedekind, and Felix Neumaier, and Bernd Neumaier, and Marcus Holschbach
January 2017, Journal of medicinal chemistry,
Copied contents to your clipboard!